Surgery for malignant pleural mesothelioma

Annals of Diagnostic Pathology

Volumn 13, Issue 1, 2009, Pages 65-72

  Rice, David ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Extrapleural pneumonectomy; Malignant pleural mesothelioma; Surgery

Indexed keywords

HUMANS; MESOTHELIOMA; NEOPLASM STAGING; PLEURAL NEOPLASMS; PNEUMONECTOMY; TREATMENT OUTCOME;

EID: 57949112735     PISSN: 10929134     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anndiagpath.2008.11.001     Document Type: Review

References (33)

1. Ruffie P., Feld R., Minkin S., et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 7 8 (1989) 1157-1168
2. Merritt N., Blewett C.J., Miller J.D., et al. Survival after conservative (palliative) management of pleural malignant mesothelioma. J Surg Oncol 78 (2001) 171-174
3. Muers M.F., Stephens R.J., Fisher P., et al. MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 371 9625 (2008) 1685-1694
4. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 14 (2003) 2636-2644
5. van Meerbeeck J.P., Gaafar R., Manegold C., et al., European Organisation for Research and Treatment of Cancer Lung Cancer Group. National Cancer Institute of Canada. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23 28 (2005) 6881-6889
6. Flores R.M., Akhurst T., Gonen M., et al. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 126 1 (2003) 11-16
7. Erasmus J.J., Truong M.T., Smythe W.R., et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg 129 6 (2005) 1364-1370
8. Flores R.M., Akhurst T., Gonen M., et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 132 4 (2006) 763-768
9. Rice D.C., Erasmus J.J., Stevens C.W., et al. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg 80 6 (2005) 1988-1992
10. Gupta V., Mychalczak B., Krug L., et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 63 4 (2005) 1045-1052
11. Lee T.T., Everett D.L., Shu H.K., Jahan T.M., et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 124 6 (2002) 1183-1189
12. Rusch V.W., Rosenzweig K., Venkatraman E., et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122 4 (2001) 788-795
13. Rice D.C., Stevens C.W., Correa A.M., et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 84 5 (2007) 1685-1692
14. Sugarbaker D.J., Flores R.M., Jaklitsch M.T., et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117 1 (1999) 54-63
15. Baldini E.H., Recht A., Strauss G.M., et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 63 2 (1997) 334-338
16. Yajnik S., Rosenzweig K.E., Mychalczak B., et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 56 5 (2003) 1319-1326
17. Weder W., Kestenholz P., Taverna C., et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 22 17 (2004) 3451-3457
18. Allen A.M., Den R., Wong J.S., et al. Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy. Int J Radiat Oncol Biol Phys 68 5 (2007) 1366-1374
19. Krug L., Pass H., Rusch V., et al. A multicenter Phase 2 trial of neo-adjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT) for stage I-III malignant mesothelioma (MPM). J Clin Oncol (2007) [ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 7561. Abstract]
20. de Perrot M., Uy K., Anraku M., et al. Risk factors for major complications after extrapleural pneumonectomy for malignant pleural mesothelioma. Ann Thorac Surg 85 4 (2008) 1206-1210
21. Miles E.F., Larrier N.A., Kelsey C.R., et al. Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience. Int J Radiat Oncol Biol Phys 71 4 (2008) 1143-1150
22. Rusch V., Saltz L., Venkatraman E., et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 12 6 (1994) 1156-1163
23. Pass H.I., Kranda K., Temeck B.K., et al. Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol 4 3 (1997) 215-222
24. Moskal T.L., Dougherty T.J., Urschel J.D., et al. Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up. Ann Thorac Surg 66 4 (1998) 1128-1133
25. Friedberg J.S., Mick R., Stevenson J., et al. A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg 75 3 (2003) 952-959
26. Colaut F., Toniolo L., Vicario G., et al. Pleurectomy/decortication plus chemotherapy: outcomes of 40 cases of malignant pleural mesothelioma. Chir Ital 56 6 (2004) 781-786
27. Richards W.G., Zellos L., Bueno R., et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 24 10 (2006) 1561-1567
28. Lucchi M., Chella A., Melfi F., et al. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg 31 3 (2007) 529-533
29. van Ruth S., Baas P., Haas R.L., et al. Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann Surg Oncol 10 2 (2003) 176-182
30. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgicalmanagement of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008 Mar;135(3):620-6, 626.
31. Flores R.M., Zakowski M., Venkatraman E., et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2 10 (2007) 957-965
32. Martin-Ucar A.E., Nakas A., Edwards J.G., and Waller D.A. Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma. Eur J Cardiothorac Surg 31 5 (2007) 765-770
33. Treasure T., Tan C., Lang-Lazdunski L., and Waller D. The MARS trial: mesothelioma and radical surgery. Interact Cardiovasc Thorac Surg 5 1 (2006) 58-59